EUVIMEDSkopri EUVIMED
Open access

Performance of Xpert ® MTB/RIF and Determine™ TB-LAM Ag in HIV-infected adults in peri-urban sites in Zambia

M P Kasaro, O N Chilyabanyama, N S Shah, B Muluka, N Kapata, A Krüüner, I Mwaba, K Kaunda, W L Coggin, X J Wen, G Henostroza, S Reid

Public Health Action · 2020-12 · 10 (4) · 134-140

DOI: 10.5588/pha.20.0010 ↗

At a glance

Journal article in Public Health Action, published online on 2020-12-01. Written by M P Kasaro and 11 co-authors. Institution: Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. Cited 3 times so far (Crossref). The full text is freely available in PubMed Central. Funded by: CGH CDC HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Setting

Peri-urban health facilities providing HIV and TB care in Zambia.

Objective

To evaluate 1) the impact of Xpert ® MTB/RIF on time-to-diagnosis, treatment initiation, and outcomes among adult people living with HIV (PLHIV) on antiretroviral therapy (ART); and 2) the diagnostic performance of Xpert and Determine™ TB-LAM Ag assays.

Design

Quasi-experimental study design with the first cohort evaluated per standard-of-care (SOC; first sputum tested using smear microscopy) and the second cohort per an algorithm using Xpert as initial test (intervention phase; IP). Xpert testing was provided onsite in Chongwe District, while samples were transported 5–10 km in Kafue District. TB was confirmed using mycobacterial culture.

Results

Among 1350 PLHIV enrolled, 156 (15.4%) had confirmed TB. Time from TB evaluation to diagnosis ( P = 0.018), and from evaluation to treatment initiation ( P = 0.03) was significantly shorter for IP than for SOC. There was no difference in all-cause mortality (7.0% vs. 8.6%). TB-LAM Ag showed higher sensitivity with lower CD4 cell count: 81.8% at CD4 < 50 cells/mm 3 vs. 31.7% overall.

Conclusion

Xpert improved time to diagnosis and treatment initiation, but there was no difference in all-cause mortality. High sensitivity of Determine TB-LAM Ag at lower CD4 count supports increased use in settings providing care to PLHIV, particularly with advanced HIV disease.

Subjects

Author keywords

HIVMycobacterium tuberculosisZambia

Authors and institutions

  • Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
  • Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Ministry of Health Zambia National TB Programme, Lusaka, Zambia.
  • University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

  • CGH CDC HHS

Cite

APA

Kasaro, M. P., Chilyabanyama, O. N., Shah, N. S., Muluka, B., Kapata, N., Krüüner, A., Mwaba, I., Kaunda, K., Coggin, W. L., Wen, X. J., Henostroza, G., & Reid, S. (2020). Performance of Xpert ® MTB/RIF and Determine™ TB-LAM Ag in HIV-infected adults in peri-urban sites in Zambia. Public Health Action, 10(4), 134-140. https://doi.org/10.5588/pha.20.0010

Vancouver

Kasaro MP, Chilyabanyama ON, Shah NS, Muluka B, Kapata N, Krüüner A, et al. Performance of Xpert ® MTB/RIF and Determine™ TB-LAM Ag in HIV-infected adults in peri-urban sites in Zambia. Public Health Action. 2020;10(4):134-140. doi:10.5588/pha.20.0010

BibTeX
@article{Kasaro2020,
  author = {Kasaro, M P and Chilyabanyama, O N and Shah, N S and Muluka, B and Kapata, N and Krüüner, A and Mwaba, I and Kaunda, K and Coggin, W L and Wen, X J and Henostroza, G and Reid, S},
  title = {Performance of Xpert ® MTB/RIF and Determine™ TB-LAM Ag in HIV-infected adults in peri-urban sites in Zambia},
  journal = {Public Health Action},
  year = {2020},
  volume = {10},
  number = {4},
  pages = {134--140},
  doi = {10.5588/pha.20.0010}
}
Start for free →